Dabrafenib

BreastfeedingPediatric
  • TRADE NAME: Tafinlar (Novartis)
  • INDICATIONS: Melanoma (unresectable or metastatic) in patients with BRAF V600E mutation
  • CLASS: BRAF inhibitor, Kinase inhibitor
  • HALF-LIFE: 8 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Strong CYP3A4 or CYP2C8 inducers or inhibitors

PREGNANCY CATEGORY: D

Our database has 96 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OCULAR
OTHER


Page last updated 09/25/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric